Immunostaining for ER and PgR has been reported to be useful for diagnosing metastatic tumors from breast cancer, although 32% and 12% of primary gastric cancer cases are positive for ER and PgR, respectively. This evidence concerns the gene ESR1 and breast carcinoma.